31 October 2022>: Clinical Research
hOGG1 rs1052133 Polymorphism and Prostate Cancer Risk: A Chinese Case-Control Study and Meta-Analysis
Hanjiang Xu 123BCDEF , Meng Zhang 123BCDEF , Zongyao Hao 123AC , Chaozhao Liang 123A*DOI: 10.12659/MSM.938012
Med Sci Monit 2022; 28:e938012
Table 3 Correlation between hOGG1 (rs1052133) genotypes and different clinicopathological features of prostate cancer.
Genotype | PSA level, ng/m | Gleason score | TNM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
<10 (%) | 10–20 (%) | >20 (%) | OR (95% CI) | P- value | ≤7 (%) | >7 (%) | OR (95% CI) | P-value | ≤T3 (%) | >T3 (%) | OR (95% CI) | P-value | |
CC | 5 (10.9) | 9 (14.1) | 6 (12.0) | 1 (Ref.) | 11 (11.1) | 9 (14.8) | 1 (Ref.) | 13 (10.9) | 7 (17.1) | 1 (Ref.) | |||
CG | 23 (50.0) | 40 (62.5) | 22 (44.0) | 1.02 (0.41, 2.53) | 0.974 | 53 (53.5) | 32 (52.5) | 0.74 (0.28, 2.01) | 0.545 | 63 (52.9) | 22 (53.7) | 0.65 (0.23, 1.91) | 0.414 |
GG | 18 (39.1) | 15 (23.4) | 22 (44.0) | 0.57 (0.22, 1.46) | 0.240 | 35 (35.4) | 20 (32.8) | 0.70 (0.25, 2.00) | 0.498 | 43 (36.1) | 12 (29.3) | 0.52 (0.17, 1.64) | 0.250 |
CG+GG | 41 (89.1) | 55 (85.9) | 44 (88.0) | 0.8 (0.33, 1.9) | 0.609 | 88 (88.9) | 52 (85.2) | 0.72 (0.28, 1.90) | 0.500 | 106 (89.1) | 34 (82.9) | 0.60 (0.22, 1.70) | 0.308 |
C allele | 33 (35.9) | 58 (45.3) | 34 (34.0) | 1 (Ref.) | 75 (37.9) | 50 (41.0) | 1 (Ref.) | 89 (37.4) | 36 (43.9) | 1 (Ref.) | |||
G allele | 59 (64.1) | 70 (54.7) | 66 (66.0) | 0.71 (0.47, 1.08) | 0.114 | 123 (62.1) | 72 (59.0) | 0.88 (0.55, 1.39) | 0.580 | 149 (62.6) | 46 (56.1) | 0.76 (0.46, 1.27) | 0.298 |
PSA – prostatic specific antigen; TNM – tumor node metastasis; OR – odds ratio; Ref. – reference; CI – confidential interval. |